Tag Archives: GSK

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Posted in Corporate Responsibility, Deals, Emerging Markets, Global, IP, Market Access, pricing | Also tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

One Company, One Defining Moment

Being an observer rather than a participant in the drugs business makes it easier to sense those defining moments when something fundamental has changed, a limit is reached, and a new order emerges to reset the basic license to operate.   As Pharm Exec monthly goes to press, one such moment appears to have arrived, with […]
Posted in Emerging Markets, Global, Strategy | Also tagged , , , , , , , | 1 Comment

GSK Goes DTC for London Olympics

It’s an unusual sight in the UK — a television commercial for a Big Pharma company. But among the cultural and commercial innovations being attributed to the London Olympic Games is GSK’s first UK consumer-facing corporate brand campaign, showcasing its anti-doping operations. The TV ad debuted on July 16; this week, the company’s campaign went […]
Posted in Advertising, Europe, Global | Also tagged , , , , | 2 Comments

Comply or Die: Introducing GSK's New Corporate Integrity Agreement

Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy). Despite its egalitarian trappings, the healthcare “ecosystem” is still dominated by the most […]
Posted in Agency Insight, compliance, Corporate Responsibility, Legal, Marketing, Regulatory, Sales, Strategy | Also tagged , , , , , , , , , | Leave a comment

GSK: A Rebuffed Suitor for the Moment

By Patricia Van Arnum. Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.  Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK. HGS has authorized its board of directors to explore strategic alternatives for the company, including a […]
Posted in Deals, Guest Blog | Also tagged , , , | 1 Comment
  • Categories

  • Meta